Three patients with different types of xanthomata and hyperlipoproteinaemia are described. One patient had eruptive xanthomata with a Fredrickson Type V hyperlipaemia, the second had tuberose xanthomata and Type III hyperlipaemia, while the third had eruptive, tuberose and tendon sheath xanthomata as well as flat xanthomata of palms without continuous evidence of hyperlipaemia and with impaired glucose tolerance. This patient had shown at times features of Fredrickson Type III hyperlipaemia. The different types of cutaneous xanthomata did not correlate with specific hyperlipaemias. Patients with hyperlipaemia and xanthomatosis appear to be more prone to develop occlusive vascular disease than those without skin lesions. Treatment with diet and serum lipid lowering drugs (nicotinic acid derivatives, Clofibrate, Cholestyramine and thyroid preparations) is discussed.

Keywords:
Xanfhomatosis, Hyperlipaemia, Classification of hyperlipoproteinaemia, Xanthomata in hyperlipoproteinaemia, Hyperlipoproteinaemia, Palmar xanthomata in type II
This content is only available via PDF.
© 1972 S. Karger AG, Basel
1972
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.